12456 Changes In High-sensitivity Cardiac Troponin I After 12 Months Of Gender Affirming Hormone Therapy

• Published in: Journal of the Endocrine Society 2024-10, Vol.8 (Supplement_1)
• Main Authors: Cheung, A S, Bretherton, I, Perera, S, Singh, L, Chiang, C Y
• Format: Article
• Language: English
• Subjects: Abstract
• ISSN: 2472-1972; 2472-1972
• DOI: 10.1210/jendso/bvae163.1571

Abstract Disclosure: A.S. Cheung: None. I. Bretherton: None. S. Perera: None. L. Singh: None. C.Y. Chiang: None. Background: Due to differences in cardiac size and physiology between cisgender men and women, sex-specific reference cut-offs are recommended for Abbott high-sensitivity cardiac troponin I (hsTnI) to improve diagnostic accuracy of acute coronary syndrome. There are no prospective studies which examine the impact of gender affirming hormone therapy on hsTnI. We aimed to prospectively evaluate the change in hsTnI in transgender men and women newly commencing gender affirming hormone therapy (GAHT) compared to cisgender men and cisgender women over 12 months. Methods: Transgender men (TM) and transgender women (TW) aged >18 years newly commencing GAHT were recruited from outpatient endocrine clinics. Cisgender men (CM) and cisgender women (CW) were recruited from local community advertisements. Fasting serum collected at baseline and 12 months was frozen at - 80 degrees with batch analysis on the Abbott ARCHITECT i2000 hsTnI assay. One-way ANOVA analysis was performed on age, baseline hsTnI, repeat hsTnI, and change in hsTnI over 12 months between the 4 groups. Chi-square was used to analyze categorical status of detectable hsTnI using a Limit of Quantitation of < 2 ng/L. Data are presented as mean (standard deviation). P value < 0.05 is defined as significant. Results: Baseline samples were available for 263 participants, and 103 had paired baseline and repeat hsTnI samples. The mean age of participants was 31 years ± 12.4 and none had renal impairment. The TM group was younger (n=58, 25.7 ± 6.2 years old, p < 0.005) compared to the other 3 groups (TW n=56, 33.8 ± 15.7 years, CM n=70, 32.7 ± 13.8 years, CF n=79, 31.2 ± 10.7 years). At baseline, CM (2.1 ± 2.4 ng/L) had comparable hsTnI to TW (1.8 ± 2.1, p = 0.9), but higher hsTnI compared to CF (0.8 ±1.1, p < 0.001) and TM (1.1 ± 1.8, p = 0.03). At 12 months follow-up, CM (2.5 ± 2.8ng/L) had higher hsTnI compared to TW (0.9 ± 0.9, p = 0.004), CF (0.6 ±0.6, p < 0.001) and TM (0.9 ± 0.5, p = 0.002). There was a significant decrease in hsTnI after 12 months in TW (-1.4 ± 2.2) compared with CM (0.6 ± 1.9, p = 0.013). Detectable baseline hsTnI became undetectable (